PL2247585T3 - Krystaliczne postacie N-[2-(dietyloamino)etylo]-5-[(5-fluoro-1,2-dihydro-2-okso-3H-indol-3-ilideno)metylo]-2,4-dimetylo-1H-pirolo-3-karboksamidu i sposoby ich otrzymywania - Google Patents

Krystaliczne postacie N-[2-(dietyloamino)etylo]-5-[(5-fluoro-1,2-dihydro-2-okso-3H-indol-3-ilideno)metylo]-2,4-dimetylo-1H-pirolo-3-karboksamidu i sposoby ich otrzymywania

Info

Publication number
PL2247585T3
PL2247585T3 PL09717772T PL09717772T PL2247585T3 PL 2247585 T3 PL2247585 T3 PL 2247585T3 PL 09717772 T PL09717772 T PL 09717772T PL 09717772 T PL09717772 T PL 09717772T PL 2247585 T3 PL2247585 T3 PL 2247585T3
Authority
PL
Poland
Prior art keywords
ylidene
indol
carboxamide
diethylamino
pyrrole
Prior art date
Application number
PL09717772T
Other languages
English (en)
Inventor
Nesrin Mohamad
Roland Boese
Rüdiger Latz
Hans-Günter Striegel
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of PL2247585T3 publication Critical patent/PL2247585T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
PL09717772T 2008-03-06 2009-03-05 Krystaliczne postacie N-[2-(dietyloamino)etylo]-5-[(5-fluoro-1,2-dihydro-2-okso-3H-indol-3-ilideno)metylo]-2,4-dimetylo-1H-pirolo-3-karboksamidu i sposoby ich otrzymywania PL2247585T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08004143A EP2098521A1 (en) 2008-03-06 2008-03-06 Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
PCT/EP2009/001568 WO2009109388A1 (en) 2008-03-06 2009-03-05 Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation
EP09717772.9A EP2247585B1 (en) 2008-03-06 2009-03-05 Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation

Publications (1)

Publication Number Publication Date
PL2247585T3 true PL2247585T3 (pl) 2014-09-30

Family

ID=39590734

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09717772T PL2247585T3 (pl) 2008-03-06 2009-03-05 Krystaliczne postacie N-[2-(dietyloamino)etylo]-5-[(5-fluoro-1,2-dihydro-2-okso-3H-indol-3-ilideno)metylo]-2,4-dimetylo-1H-pirolo-3-karboksamidu i sposoby ich otrzymywania

Country Status (15)

Country Link
US (1) US20110034703A1 (pl)
EP (3) EP2098521A1 (pl)
JP (1) JP2011513349A (pl)
KR (1) KR101604501B1 (pl)
CN (1) CN101965342B (pl)
AU (1) AU2009221458A1 (pl)
CA (1) CA2714441A1 (pl)
EA (1) EA020067B1 (pl)
ES (1) ES2478821T3 (pl)
IL (1) IL207984A (pl)
PL (1) PL2247585T3 (pl)
PT (1) PT2247585E (pl)
SI (1) SI2247585T1 (pl)
WO (1) WO2009109388A1 (pl)
ZA (1) ZA201005796B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220071A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
ES2392762T3 (es) 2008-06-13 2012-12-13 Medichem, S.A. Procedimiento para preparar una sal de malato de 2-indolinona sustituida con 3-pirrol
CN102197034A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的新型多晶型物及其制备方法
JP2012500837A (ja) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド 新規な結晶型およびその調製方法
US20130210885A1 (en) 2010-01-29 2013-08-15 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2013188283A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
CN103833733B (zh) * 2012-11-21 2017-08-25 广东东阳光药业有限公司 一种替尼类药物新晶型
ES2813877T3 (es) 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN106884206A (zh) * 2017-03-17 2017-06-23 青岛大学 一种有机非线性光学晶体用籽晶的生长方法
JP7009534B2 (ja) 2020-03-12 2022-01-25 住友理工株式会社 バッテリーパック用断熱材およびバッテリーパック

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE331514T1 (de) 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
JP3663382B2 (ja) * 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
CN100364991C (zh) * 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US7119209B2 (en) * 2002-02-15 2006-10-10 Pharmacia & Upjohn Company Process for preparing indolinone derivatives

Also Published As

Publication number Publication date
EP2098521A1 (en) 2009-09-09
ZA201005796B (en) 2011-04-28
KR20100125300A (ko) 2010-11-30
PT2247585E (pt) 2014-07-17
EP2247585A1 (en) 2010-11-10
CN101965342B (zh) 2014-07-30
EA201001243A1 (ru) 2011-04-29
US20110034703A1 (en) 2011-02-10
CN101965342A (zh) 2011-02-02
ES2478821T3 (es) 2014-07-23
EP2604603A1 (en) 2013-06-19
CA2714441A1 (en) 2009-09-11
KR101604501B1 (ko) 2016-03-17
EP2247585B1 (en) 2014-04-30
SI2247585T1 (sl) 2014-08-29
IL207984A (en) 2016-07-31
IL207984A0 (en) 2010-12-30
WO2009109388A1 (en) 2009-09-11
WO2009109388A8 (en) 2010-10-07
JP2011513349A (ja) 2011-04-28
EA020067B1 (ru) 2014-08-29
AU2009221458A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
ZA201005796B (en) Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation
PT3168218T (pt) Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento
ZA201001860B (en) Pyridazinone derivatives and use thereof as p2z7 receptor inhibitors
DK2349137T3 (da) Enhed til brug sammen med en stomipose
ZA200902638B (en) Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for diabetes
EP1971296A4 (en) POSTERIOR DYNAMIC STABILIZATION OF THE VERTEBRAL COLUMN
ZA201000326B (en) Methods for modulating gpr119 g protein-coupled receptor and selected compounds
EP2328934A4 (en) T cell Receptor Antibodies and Method of Use
ATE465169T1 (de) Hemmstoffe des progesteron-rezeptors
IL208204A0 (en) Her2/neu-specific antibodies and methods of using same
EP2233172A4 (en) SYSTEM FOR STABILIZING BLOOD PRESSURE WITH TRANSDERMAL STIMULATION
EP2133331A4 (en) FIVE-GLASS HETEROCYCLIC DERIVATIVE AND ITS USE IN MEDICAL PURPOSES
IL202834A0 (en) Phthalazinone derivatives as inhibitors of parp-1
HUS1800044I1 (hu) Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére
IL225167A (en) Annotations (para-methoxy) phenyl-sulfonamide, n- (isobutyl), n - [(r2) - hydroxy- (r3) - benzyl-profile]
PT2313087T (pt) Forma de dosagem farmacêutica para libertação imediata de um derivado de indolina
PL2214607T3 (pl) System i metoda leczenia nadciśnienia tętniczego lub hipotensji
WO2010010454A3 (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
ZA201007611B (en) Process for the preparation of benzo-used heteroaryl sulfamates and crystalline form of n-(((2s)-6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methylsulfamine
IL210141A0 (en) Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide
PL2274303T3 (pl) Sposoby otrzymywania sunitynibu i jego soli
ZA201008139B (en) Means for fixing of screening media,and use of such means
EP2164078A4 (en) USE OF PLASMA-SYNTHETIZED PYROL DERIVED POLYMERS FOR NEUROSAL PROTECTION AND RE-CONNECTION OF THE NERVOUS SYSTEM
SI2220027T1 (sl) Polimorfna oblika N-(4-(trifluorometil)benzil)-4-metoksibutiramid
IL208850A (en) Identification analytes containing 2– (6 – hydroxy – 3 – oxo – 3 h– xanthan – 9 – ile) –5– (2– (3 - ((2 – phenylpyrimidine – 5 – carboxamido) methyl) phenylsulfonamido) ethyl carbamoyl) Benzoic acid And / or n-converted-2-phenylpyrimidine-5-carboxamide